GLSI
Closed
Greenwich Lifesciences inc
9.05
-0.02 (-0.22%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 9.07
Day's Range: 8.97 - 9.6
Send
sign up or login to leave a comment!
When Written:
13.31
Greenwich Lifesciences Inc. is a clinical-stage biopharmaceutical company that is focused on the development of immunotherapy treatments for breast cancer. The company's lead product candidate is GP2, a peptide-based immunotherapy that is designed to prevent the recurrence of breast cancer in patients who have previously undergone surgery. GP2 is currently in Phase III clinical trials and has received Fast Track and Orphan Drug designations from the FDA. Greenwich Lifesciences was founded in 2016 and is headquartered in Stafford, Texas.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








